EA201590321A1 - Дейтерированный барицитиниб - Google Patents

Дейтерированный барицитиниб

Info

Publication number
EA201590321A1
EA201590321A1 EA201590321A EA201590321A EA201590321A1 EA 201590321 A1 EA201590321 A1 EA 201590321A1 EA 201590321 A EA201590321 A EA 201590321A EA 201590321 A EA201590321 A EA 201590321A EA 201590321 A1 EA201590321 A1 EA 201590321A1
Authority
EA
Eurasian Patent Office
Prior art keywords
deadered
baricitinib
formula
compound
pharmaceutically acceptable
Prior art date
Application number
EA201590321A
Other languages
English (en)
Other versions
EA031716B1 (ru
Inventor
Роджер Д. Тунг
Original Assignee
Консерт Фармасьютикалс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Консерт Фармасьютикалс Инк. filed Critical Консерт Фармасьютикалс Инк.
Publication of EA201590321A1 publication Critical patent/EA201590321A1/ru
Publication of EA031716B1 publication Critical patent/EA031716B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

Настоящее изобретение согласно одному варианту осуществления относится к соединению формулы Iили его фармацевтически приемлемой соли, где переменные, показанные в формуле I, определены в описании.
EA201590321A 2012-08-17 2013-08-15 Дейтерированный барицитиниб EA031716B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261684196P 2012-08-17 2012-08-17
US201361780661P 2013-03-13 2013-03-13
PCT/US2013/055170 WO2014028756A1 (en) 2012-08-17 2013-08-15 Deuterated baricitinib

Publications (2)

Publication Number Publication Date
EA201590321A1 true EA201590321A1 (ru) 2015-06-30
EA031716B1 EA031716B1 (ru) 2019-02-28

Family

ID=49034261

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590321A EA031716B1 (ru) 2012-08-17 2013-08-15 Дейтерированный барицитиниб

Country Status (10)

Country Link
US (3) US9540367B2 (ru)
EP (2) EP2885303B1 (ru)
AU (1) AU2013302519B2 (ru)
BR (1) BR112015003153A2 (ru)
CA (1) CA2880083A1 (ru)
EA (1) EA031716B1 (ru)
ES (1) ES2717279T3 (ru)
IN (1) IN2015DN01102A (ru)
MX (1) MX361499B (ru)
WO (1) WO2014028756A1 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2601410C1 (ru) * 2015-11-13 2016-11-10 ЗАО "Р-Фарм" {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ
RU2603959C1 (ru) * 2015-11-13 2016-12-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") ДИХЛОРАЦЕТАТ {3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-ПИРАЗОЛ-1-ИЛ]-1-ЭТИЛСУЛЬФОНИЛ-АЗЕТИДИН-3-ИЛ}-АЦЕТОНИТРИЛА В КАЧЕСТВЕ ИНГИБИТОРА ЯНУС КИНАЗ

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2885303B1 (en) 2012-08-17 2018-12-26 CoNCERT Pharmaceuticals, Inc. Deuterated baricitinib
US9938283B2 (en) 2014-05-01 2018-04-10 Sun Pharmaceutical Industries Limited Crystalline form of baricitinib
AR101504A1 (es) 2014-08-11 2016-12-21 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
DK3179992T3 (da) 2014-08-11 2022-07-11 Acerta Pharma Bv Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
WO2016125080A2 (en) * 2015-02-02 2016-08-11 Sun Pharmaceutical Industries Limited Process for the preparation of baricitinib and an intermediate thereof
CN107334738B (zh) * 2016-04-28 2021-02-09 天津科伦药物研究有限公司 一种含巴瑞克替尼的药物组合物及其制备方法和用途
US20200281857A1 (en) 2017-11-22 2020-09-10 Dauntless 1, Inc. Therapeutic compound formulations
US20200353419A1 (en) 2017-11-22 2020-11-12 Dauntless 1, Inc. Membrane emulsification device for microsphere creation
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
UA127925C2 (uk) 2018-03-30 2024-02-14 Інсайт Корпорейшн Лікування гнійного гідраденіту з використанням інгібіторів jak
CN112567247A (zh) 2018-04-13 2021-03-26 因赛特公司 用于移植物抗宿主病的生物标志物
AU2020232757A1 (en) 2019-03-05 2021-10-07 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
WO2020191041A2 (en) 2019-03-19 2020-09-24 Incyte Corporation Biomarkers for vitiligo
WO2020236950A1 (en) 2019-05-21 2020-11-26 Dauntless 1, Inc. Therapeutic microsphere formulations containing charged polymers
WO2021072098A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
JP2023506118A (ja) 2019-10-16 2023-02-15 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
JP2023552424A (ja) 2020-12-04 2023-12-15 インサイト・コーポレイション 皮膚疾患の治療のためのビタミンｄ類似体を有するｊａｋ阻害剤
EP4274578A1 (en) 2021-01-11 2023-11-15 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
ATE372966T1 (de) 1994-03-25 2007-09-15 Isotechnika Inc Verbesserung der effektivität von arzneimitteln duren deuterierung
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
DK1104760T3 (da) 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
IL158306A0 (en) 2001-05-03 2004-05-12 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EA007395B3 (ru) 2002-01-22 2018-02-28 Уорнер-Ламберт Компани Ллс 2-(ПИРИДИН-2-ИЛАМИНО)ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНЫ
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
JP2009511481A (ja) 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US20080103122A1 (en) 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US7718754B2 (en) 2007-07-30 2010-05-18 Kao Corporation Promoter for polycondensation reaction
AU2009223640B2 (en) * 2008-03-11 2013-07-04 Incyte Holdings Corporation Azetidine and cyclobutane derivatives as jak inhibitors
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
AU2010206683B2 (en) 2009-01-23 2016-05-05 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
EP2885303B1 (en) 2012-08-17 2018-12-26 CoNCERT Pharmaceuticals, Inc. Deuterated baricitinib

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2601410C1 (ru) * 2015-11-13 2016-11-10 ЗАО "Р-Фарм" {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ
RU2603959C1 (ru) * 2015-11-13 2016-12-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") ДИХЛОРАЦЕТАТ {3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-ПИРАЗОЛ-1-ИЛ]-1-ЭТИЛСУЛЬФОНИЛ-АЗЕТИДИН-3-ИЛ}-АЦЕТОНИТРИЛА В КАЧЕСТВЕ ИНГИБИТОРА ЯНУС КИНАЗ
WO2017082760A1 (ru) * 2015-11-13 2017-05-18 Акционерное Общество "Р-Фарм" (Ao "Р-Фарм") Дихлорацетат {3-[4-(7н-пирроло[2,3-d] пиримидин-4-ил)-пиразол-1-ил]-1-этилсульфонил-азетидин-3-ил}-ацетонитрила в качестве ингибитора янус киназ

Also Published As

Publication number Publication date
US9931343B2 (en) 2018-04-03
ES2717279T3 (es) 2019-06-20
CA2880083A1 (en) 2014-02-20
US10842792B2 (en) 2020-11-24
EP2885303A1 (en) 2015-06-24
EA031716B1 (ru) 2019-02-28
AU2013302519A1 (en) 2015-02-12
US20180221374A1 (en) 2018-08-09
BR112015003153A2 (pt) 2017-07-04
EP3492472A1 (en) 2019-06-05
EP2885303B1 (en) 2018-12-26
MX2015002040A (es) 2015-06-05
AU2013302519B2 (en) 2017-11-02
US20150218158A1 (en) 2015-08-06
MX361499B (es) 2018-12-06
IN2015DN01102A (ru) 2015-06-26
US20170189406A1 (en) 2017-07-06
WO2014028756A1 (en) 2014-02-20
US9540367B2 (en) 2017-01-10

Similar Documents

Publication Publication Date Title
EA201590321A1 (ru) Дейтерированный барицитиниб
EA201590296A1 (ru) Дейтерированный ибрутиниб
UY34156A (es) Compuestos inhibidores de metaloenzimas
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201590534A1 (ru) Новые бициклические производные
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
EA201790923A1 (ru) Производные бетулина
UY34654A (es) Inhibidores de la beta-secretasa
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
CR20150271A (es) Peptidos como agonistas de oxitocina
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
EA201690894A1 (ru) Феноксиэтилы
TR201821285T4 (tr) CCR3 antagonisti içeren farmasötik formülasyonlar.
EA201592183A1 (ru) Ингибиторы bace
CR20150084A (es) 2-oxo-2,3-dihidro-indoles
MX2015008829A (es) Momelotinib deuterado.
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
UY33976A (es) Derivados de pirazolo-pirimidina.
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU